Shares of IsoRay Inc. (AMEX: ISR), developer, manufacturer and seller of isotope-based medical products and devices for the treatment of cancer and other serious diseases, are continuing to rally in trading today.
At last check, ISR shares were trading 15.38% higher at $1.35 on above average volume of 3.42 million. The stock has gained 100% in the last three trading sessions.
ISR shares are gaining momentum after the company announced that its Cesium-131 prostate cancer treatment was featured on the Discovery Channel.
Recently, the Richland, Washington-based company also announced that its GliaSite® radiation therapy system earned the European CE Mark. The European CE Mark allows immediate sale of GliaSite in 31 European countries.
GliaSite is the world’s only balloon catheter device used in the treatment of brain cancer. According to Dwight Babcock, Chairman and CEO of IsoRay, the CE Mark opens the door to revenue opportunities in international markets.
Recent Comments